Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab + dose adjusted EPOCH
R-DA-EPOCH
Routinely available
Local application
29/03/2023
Indication
Treatment of primary mediastinal B-cell lymphoma.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local guidance for prescribing
Formulation
Rituximab with dose adjusted EPOCH
Comments
-